European Health Data & Evidence Network (EHDEN)

As an EHDEN Certified SME, we can help you map your healthcare data to the OMOP Common Data Model.

Are you an EHDEN data partner?

Imosphere can provide various data harmonisation services to EHDEN Data Partners. Our team's expertise and significant experience will ensure the successful transformation of your data and the creation of an OHDSI analytical infrastructure.

Our services

Our EHDEN certification means that the cost of our services are funded via grants. These services include:

  • Create new data transformation and analytical infrastructure (100,000 EUR grant)
  • Revise your existing data transformation and analytical infrastructure (70,000 EUR grant)
  • Inspect your completed data transformation and analytical infrastructure (30,000 EUR grant)

Additional analytics support

  • Consultancy on structuring of data collection tools and data structures to support data analysis
  • Provision of a healthcare analytics and data discovery platform for cohort identification, data discovery and visualisation of large-scale health data

Experts in data mapping and ETL

We have a breadth of experience and understanding of coding systems, ETL and analytical requirements across a whole range of healthcare data. We've worked with a variety of data sets for over 25 years and a significant part of our work involves mapping data sources, and performing ETL into our knowledge warehouse.

Global projects

We have successfully worked with OMOP CDM early adopters across the globe:

Major US medical college

The project used OMOP as the data repository and included diagnostic, procedural, lab and medication data.

Health Science Centres

Used OMOP to unify multiple medical data sources into a single database, providing population health analytics on 0.25M patients.

Social Determinants of Health

Using an OMOP database as the source for a project that combined social determinant data with clinical data.

Get in touch

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.